Skip to main content
2024 Guide to Patient Support Services

Karyopharm Therapeutics

2024 PSS Guide

Karyopharm KaryForward Patient Support Services

Karyopharm Therapeutics offers comprehensive patient support services through its KaryForward program to facilitate access to Karyopharm’s oncology medication, Xpovio, including reimbursement support and patient financial assistance (Table).

KaryForward Patient Support Services

KaryForward offers patients a comprehensive set of support services, including financial assistance for patients, such as copay support; reimbursement support, such as insurance benefit investigation, prior authorization, and/or appeal assistance; and patient and caregiver resources, such as support from a dedicated Nurse Case Manager regarding prescription instructions and medication side effects.

Xpovio Copay Program

The Xpovio Copay Program provides copay assistance to eligible patients with commercial insurance. Eligible patients may pay as little as $5 per month out of pocket for Xpovio, with a maximum amount of $8000 per month and an annual cap of $25,000.

See theXpovio Copay Program for eligibility criteria.

The Xpovio Copay Program is not valid for patients who are paying cash for Xpovio, when Xpovio is not covered by the patient’s commercial insurance, or when the patient’s plan reimburses the entire cost of Xpovio.

KaryForward Patient Assistance Program

The KaryForward Patient Assistance Program provides Xpovio free of charge to uninsured and underinsured patients who meet the requirement criteria.

If patients do not meet the eligibility criteria and still need assistance, KaryForward may assist in identifying alternate sources of coverage.

QuickStart Program

The QuickStart Program is available to eligible patients who are receiving their first prescription of Xpovio and cannot establish coverage or verification of coverage within 5 business days.

Call 877-527-9493 for further details about the Quick-Start Program.

Bridge Program

The Bridge Program enables the prescriber to provide eligible patients with an emergency supply of Xpovio at no cost if the patient has an unexpected disruption in therapy of more than 5 business days, and if the provider determines that it is medically necessary for the patient to continue therapy without interruption.

Dose Exchange Program

This new program offers support for patients who may need a dose adjustment mid-cycle. Please see the Dose Exchange Form for more details, terms and conditions, and to enroll your appropriate patients.

Application & Enrollment

Enrollment in the Xpovio Copay Program, KaryForward Patient Assistance Program, QuickStart Program, and the Bridge Program requires the completion and submission of the KaryForward Enrollment Form, which can be accessed and completed online. Alternatively, the completed enrollment form can be faxed to 833-589-1603. The type(s) of patient support services needed must be indicated on the form, and the patient and the prescribing physician are required to sign the application. Assistance with the enrollment process can be obtained by calling 877-527-9493.

Xpovio is dispensed through a specialty pharmacy. Xpovio may be sent to the preferred specialty pharmacy indicated on the enrollment form or to the patient’s home.

TABLE Karyopharm Therapeutics Oncology Drug

Patient support programs

Xpovio (selinexor)
Treatment of adults with multiple myeloma (MM), in combintion with bortezomib and dexamethasone, who have received ≥1 prior therapy; treatment, in combination with dexamethasone, in adults with relapsed or refractory MM who have received ≥4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody; treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after ≥2 lines of systemic therapy
Patient support programs